Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 10/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 8/20 | 0.33 |
| ▸ | BRD2 | P25440 | 5/20 | 0.33 |
| ▸ | BRD7 | Q9NPI1 | 5/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | S100B | P04271 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29048928 | 0.81 | S100B (0.38) | MPOXDHLMNAMAPTCYP2C9 | |
| SCHEMBL2384938 | 0.78 | BRD4 (0.35) | MPOXDHLMNAMAPTCYP2C9 | |
| SCHEMBL25980029 | 0.68 | ERN1 (0.47) | LMNAMAPTCYP2C9GAAS100B | |
| SCHEMBL16921627 | 0.63 | MAPT (0.36) | LMNAMAPTCYP2C9BRD4BRD9 | |
| SCHEMBL15807133 | 0.63 | MAPT (0.43) | MPOXDHLMNAMAPTGAA | |
| SCHEMBL6932284 | 0.62 | ERN1 (0.36) | LMNAMAPTCYP2C9BRD4S100B | |
| SCHEMBL18163876 | 0.59 | BRD4 (0.42) | LMNAMAPTCYP2C9BRD4BRD9 | |
| SCHEMBL17372112 | 0.59 | GRIN2D (0.42) | LMNAMAPTCYP2C9ALDH1A1KDM4E | |
| SCHEMBL2730975 | 0.58 | MPO (1.00) | MPOXDHMAPTGAAALDH1A1 | |
| SCHEMBL16651423 | 0.58 | BRD4 (0.47) | LMNAMAPTCYP2C9BRD4BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1085 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889611-B1 | COMPOSITIONS AND METHODS FOR PERFORMING METHYLATION DETECTION ASSAYS | EXACT SCIENCES CORP (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260132421-A1 | CHARACTERIZATION OF IMPURITIES IN ADENO-ASSOCIATED VIRUS (AAV) SAMPLES AND FORMULATION COMPOSITIONS TO STABILIZE AAV | REGENERON PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CARIS SCIENCE, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260103762-A1 | COMPOSITIONS AND METHODS FOR PERFORMING METHYLATION DETECTION ASSAYS | EXACT SCIENCES CORP (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260092331-A1 | METHODS AND COMPOSITIONS FOR CHARACTERIZING BLADDER CANCER | UNIV OSLO HF (NO) | 2026-04-02 | — | — | US | disclosed |
| US-20260092305-A1 | ISOLATION OF NUCLEIC ACIDS | EXACT SCIENCES CORP (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260078383-A1 | RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURES | UNIV ARIZONA STATE (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260077004-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIAC DISORDERS | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577627-B2 | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONE STATE UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4189086-B1 | PURIFICATION OF SULFONATED DNA | EXACT SCIENCES CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20030224055-A1 | Compositions and processes for inhibiting gene expression using polynucleotides | ROCHE MADISON INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003099228-A2 | COMPOSITIONS AND PROCESSES FOR INHIBITING GENE EXPRESSION USING POLYNUCLEOTIDES | MIRUS CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003100439-A2 | RECEPTOR AND SCREENING METHODS | UNIVERSITY OF SHEFFIELD (GB) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099225-A2 | COMPOSITIONS FOR DELIVERING NUCLEIC ACIDS TO CELLS | MIRUS CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030220289-A1 | Compositions for delivering nucleic acids to cells | ROCHE MADISON INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003080794-A2 | INHIBITION OF RNA FUNCTION BY DELIVERY OF INHIBITORS TO ANIMAL CELLS | MIRUS CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003068961-A2 | METHOD TO MODIFY DIFFERENTIATION OF PLURIPOTENTIAL STEM CELLS | AXORDIA LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| US-20030143204-A1 | Inhibition of RNA function by delivery of inhibitors to animal cells | LEWIS DAVID L (US) | 2003-07-31 | — | — | US | disclosed |
| CN-1433431-A | Interleukin-1 receptor antagonist-like molecules and uses thereof | AMGEN INC (US) | 2003-07-30 | — | — | CN | disclosed |
| WO-2003008573-A2 | SILENCING OF GENE EXPRESSION BY SIRNA | MILNER ANNE JOSEPHINE (GB) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577627-B2 | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions | DDX41, DDX5, DDX6 | MPO 2381/4885XDH 1701/4885LMNA 1406/4885 |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CD63, FLT4, NCL | MPO 2018/4885XDH 3901/4885LMNA 1587/4885 |
| US-20260092305-A1 | ISOLATION OF NUCLEIC ACIDS | POLRMT, POLI, FUS | MPO 4154/4885XDH 2630/4885LMNA 365/4885 |
| US-20260092331-A1 | METHODS AND COMPOSITIONS FOR CHARACTERIZING BLADDER CANCER | DNMT3A, DNMT3L, INMT | MPO 477/4885XDH 338/4885LMNA 770/4885 |
| US-20260103762-A1 | COMPOSITIONS AND METHODS FOR PERFORMING METHYLATION DETECTION ASSAYS | SEPTIN2, DNMT3B, DNMT1 | MPO 4125/4885XDH 2551/4885LMNA 1297/4885 |
| US-20260132421-A1 | CHARACTERIZATION OF IMPURITIES IN ADENO-ASSOCIATED VIRUS (AAV) SAMPLES AND FORMULATION COMPOSITIONS TO STABILIZE AAV | ADAR, SLC28A2, SLC12A2 | MPO 3979/4885XDH 2659/4885LMNA 585/4885 |
| US-20260078383-A1 | RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURES | PDCD1, TIA1, NSUN2 | MPO 2495/4885XDH 3163/4885LMNA 491/4885 |
| US-20030143204-A1 | Inhibition of RNA function by delivery of inhibitors to animal cells | NSUN2, RNASE1, NSUN3 | MPO 3832/4885XDH 2650/4885LMNA 604/4885 |
| US-20260077004-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIAC DISORDERS | KCNH2, KCNH3, KCNQ1 | MPO 4705/4885XDH 2378/4885LMNA 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.